• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Information on the total number of voting rights and shares

    8/29/25 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care
    Get the next $NYXH alert in real time by email

    REGULATED INFORMATION

    Information on the total number of voting rights and shares

    Mont-Saint-Guibert (Belgium), August 29, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

    • Share capital: EUR 6,449,871.98
    • Total number of securities carrying voting rights: 37,544,782 (all ordinary shares)
    • Total number of voting rights (= denominator): 37,544,782 (all relating to ordinary shares)
    • Number of rights to subscribe to securities carrying voting rights not yet issued: 2,775,566 (all granted subscription rights; this number excludes 493,057 subscription rights that were issued but not yet granted)

    *

    * *

    Contact:

    Nyxoah

    John Landry, CFO

    [email protected]

    Attachment

    • 2025 08 29 - Press release - Number of shares (ENG)


    Primary Logo

    Get the next $NYXH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NYXH

    DatePrice TargetRatingAnalyst
    7/31/2023Buy
    H.C. Wainwright
    7/19/2023Neutral
    Robert W. Baird
    4/21/2022$30.00Outperform
    Oppenheimer
    4/6/2022$21.00Peer Perform
    Wolfe Research
    12/21/2021$47.00Overweight
    Cantor Fitzgerald
    7/28/2021$43.00Overweight
    Cantor Fitzgerald
    7/28/2021$40.00Overweight
    Piper Sandler
    7/27/2021$43.00Buy
    Stifel
    More analyst ratings

    $NYXH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Information on the total number of voting rights and shares

    REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), August 29, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,449,871.98 Total number of securities carrying voting rights: 37,544,782 (all ordinary shares) Total number of voting rights (= denominator): 37,544,782 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 2,775,566 (all granted subscription r

    8/29/25 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Reports Second Quarter Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hyp

    8/18/25 4:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Announces Preliminary Results for the Second Quarter of 2025

    Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates.  Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to sever

    8/11/25 1:00:00 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Nyxoah S.A.

    H.C. Wainwright initiated coverage of Nyxoah S.A. with a rating of Buy

    7/31/23 8:05:01 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Robert W. Baird initiated coverage on Nyxoah S.A.

    Robert W. Baird initiated coverage of Nyxoah S.A. with a rating of Neutral

    7/19/23 7:19:37 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Nyxoah S.A. with a new price target

    Oppenheimer initiated coverage of Nyxoah S.A. with a rating of Outperform and set a new price target of $30.00

    4/21/22 7:16:59 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    SEC Filings

    View All

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    8/18/25 4:45:35 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    8/11/25 6:01:04 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    7/29/25 6:13:51 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Leadership Updates

    Live Leadership Updates

    View All

    Nyxoah Appoints John Landry as Chief Financial Officer

    Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. Mr. Landry

    11/4/24 4:45:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Appoints Scott Holstine as Chief Commercial Officer

    Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch. Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by

    7/15/24 2:00:00 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Strengthens its Executive Leadership Team

    Nyxoah Strengthens its Executive Leadership TeamFrancis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah's Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device

    11/28/23 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Financials

    Live finance-specific insights

    View All

    Nyxoah Reports Second Quarter Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hyp

    8/18/25 4:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Announces Preliminary Results for the Second Quarter of 2025

    Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates.  Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to sever

    8/11/25 1:00:00 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025

    Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Monday, August 18, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyx

    7/29/25 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nyxoah SA

    SC 13D/A - Nyxoah SA (0001857190) (Subject)

    10/10/24 4:00:17 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Nyxoah SA (Amendment)

    SC 13D/A - Nyxoah SA (0001857190) (Subject)

    5/30/24 5:20:40 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

    SC 13G/A - Nyxoah SA (0001857190) (Subject)

    2/14/24 4:17:59 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care